Optofluidics

Bruker Completes Acquisition of PhenomeX

Retrieved on: 
Tuesday, October 3, 2023
Medical Devices, Health, Genetics, Research, Science, Biotechnology, Genotype, Cell biology, BRKR, Cell, Corporation, Acquisition, EPS, Phenotype, Cryptocurrency, Mobile phone, Bruker, Optofluidics, Beacon

Bruker Corporation (Nasdaq: BRKR) today announced that it has completed the acquisition of PhenomeX, a leading provider of single-cell biology research tools, for $108 million in cash.

Key Points: 
  • Bruker Corporation (Nasdaq: BRKR) today announced that it has completed the acquisition of PhenomeX, a leading provider of single-cell biology research tools, for $108 million in cash.
  • Bruker announced the agreement to acquire PhenomeX on August 17, 2023.
  • “We are excited to welcome PhenomeX to Bruker,” commented Dr. Mark R. Munch, President of the Bruker NANO Group.
  • During its Q3 2023 earnings release, Bruker will provide more details on the expected Q4 2023 effect from PhenomeX.